{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:41:47Z","timestamp":1791837707785,"version":"4.3.4"},"reference-count":100,"publisher":"Japanese Pharmacological Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1254\/jphs.11r01cr","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T05:20:31Z","timestamp":1303104031000},"page":"6-17","source":"Crossref","is-referenced-by-count":90,"title":["Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine"],"prefix":"10.1254","volume":"116","author":[{"given":"Yukio","family":"Ago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(00)00214-X"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)01109-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Nordberg A, Lundqvist H, Hartvig P, Lilja A, L&aring;ngstr&ouml;m B. Kinetic analysis of regional (S)(&ndash;)<SUP>11<\/SUP>C-nicotine binding in normal and Alzheimer brains &mdash; in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord. 1995;9:21&ndash;27.","DOI":"10.1097\/00002093-199505000-00006"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00064-9"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/1359-6446(96)89089-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl). 2004;174:45&ndash;53.","DOI":"10.1007\/s00213-004-1794-x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, et al. Postmortem studies in schizophrenia. Schizophr. Bull. 1998;24:325&ndash;341.","DOI":"10.1093\/oxfordjournals.schbul.a033330"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Scarr E, Dean B. Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Rev Neurother. 2009;9:73&ndash;86.","DOI":"10.1586\/14737175.9.1.73"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J, et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry. 2006;63:741&ndash;747.","DOI":"10.1001\/archpsyc.63.7.741"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Gibbons AS, Scarr E, McLean C, Sundram S, Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord. 2009;116:184&ndash;191.","DOI":"10.1016\/j.jad.2008.11.015"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Wang JC, Grucza R, Cruchaga C, Hinrichs AL, Bertelsen S, Budde JP, et al. Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psychiatry. 2009;14:501&ndash;510.","DOI":"10.1038\/mp.2008.42"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Allen TB, McEvoy JP. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry. 2002;159:1244&ndash;1245.","DOI":"10.1176\/appi.ajp.159.7.1244"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Bora E, Veznedaro<I>g<\/I>lu B, Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Pharmacol. 2005;28:139&ndash;141.","DOI":"10.1097\/01.wnf.0000162555.68729.04"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry. 2008;165:82&ndash;89.","DOI":"10.1176\/appi.ajp.2007.07050724"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Nor&eacute;n U, Bj&ouml;rner A, Sonesson O, Eriksson L. Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophr Res. 2006;85:302&ndash;304.","DOI":"10.1016\/j.schres.2006.03.039"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol. 2002;25:272&ndash;275.","DOI":"10.1097\/00002826-200209000-00010"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.04.006"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res. 2008;102:88&ndash;95.","DOI":"10.1016\/j.schres.2007.12.491"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol. 2007;22:63&ndash;68.","DOI":"10.1097\/YIC.0b013e3280117feb"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Elgamal S, MacQueen G. Galantamine as an adjunctive treatment in major depression. J Clin Psychopharmacol. 2008;28:357&ndash;359.","DOI":"10.1097\/JCP.0b013e318172756c"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Holtzheimer PE 3rd, Meeks TW, Kelley ME, Mufti M, Young R, McWhorter K, et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry. 2008;23:625&ndash;631.","DOI":"10.1002\/gps.1951"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Elgamal SA, Marriott M, Macqueen GM. Electroencephalographic effects of galantamine in major depressive disorder. J Clin Neurophysiol. 2009;26:192&ndash;197.","DOI":"10.1097\/WNP.0b013e3181a184e5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Snorrason E, Stef&aacute;nsson JG. Galanthamine hydrobromide in mania. Lancet. 1991;337:557.","DOI":"10.1016\/0140-6736(91)91347-W"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181a497d7"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Iosifescu DV, Moore CM, Deckersbach T, Tilley CA, Ostacher MJ, Sachs GS, et al. Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. CNS Neurosci Ther. 2009;15:309&ndash;319.","DOI":"10.1111\/j.1755-5949.2009.00090.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Schrauwen E, Ghaemi SN. Galantamine treatment of cognitive impairment in bipolar disorder: four cases. Bipolar Disord. 2006;8:196&ndash;199.","DOI":"10.1111\/j.1399-5618.2006.00311.x"},{"issue":"1","key":"27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1360-0443.2009.02791.x","volume":"105","author":"SOFUOGLU MEHMET","year":"2010","ISSN":"https:\/\/id.crossref.org\/issn\/0965-2140","issn-type":"print"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Mann K, Ackermann K, Diehl A, Ebert D, Mundle G, Nakovics H, et al. Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology (Berl). 2006;184:115&ndash;121.","DOI":"10.1007\/s00213-005-0243-9"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Villarroya M, Garc&iacute;a AG, Marco-Contelles J, L&oacute;pez MG. An update on the pharmacology of galantamine. Expert Opin Investig Drugs. 2007;16:1987&ndash;1998.","DOI":"10.1517\/13543784.16.12.1987"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145706007103"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1124\/mol.61.5.1222"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Schilstr&ouml;m B, Ivanov VB, Wiker C, Svensson TH. Galantamine enhances dopaminergic neurotransmission <I>in vivo<\/I> via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology. 2007;32:43&ndash;53.","DOI":"10.1038\/sj.npp.1301087"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Sharp BM, Yatsula M, Fu Y. Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J Pharmacol Exp Ther. 2004;309:1116&ndash;1123.","DOI":"10.1124\/jpet.103.063586"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2008.00037.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Bullock R. Galantamine: use in Alzheimer&rsquo;s disease and related disorders. Expert Rev Neurother. 2004;4:153&ndash;163.","DOI":"10.1586\/14737175.4.2.153"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Darreh-Shori T, Soininen H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer&rsquo;s disease: a review of recent clinical studies. Curr Alzheimer Res. 2010;7:67&ndash;73.","DOI":"10.2174\/156720510790274455"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs. 2010;24:303&ndash;317.","DOI":"10.2165\/11530260-000000000-00000"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(99)00016-8"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Janhunen S, Ahtee L. Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine. Eur J Pharmacol. 2004;494:167&ndash;177.","DOI":"10.1016\/j.ejphar.2004.05.015"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Kashkin VA, De Witte P. Nicotine increases microdialysate brain amino acid concentrations and induces conditioned place preference. Eur Neuropsychopharmacol. 2005;15:625&ndash;632.","DOI":"10.1016\/j.euroneuro.2005.03.004"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Shearman E, Fallon S, Sershen H, Lajtha A. Nicotine-induced monoamine neurotransmitter changes in the brain of young rats. Brain Res Bull. 2008;76:626&ndash;639.","DOI":"10.1016\/j.brainresbull.2008.03.017"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00312-8"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology. 2002;26:583&ndash;594.","DOI":"10.1016\/S0893-133X(01)00400-6"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00105-4"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233&ndash;255.","DOI":"10.1093\/oxfordjournals.schbul.a033376"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Roman S, Badia A, Camps P, Clos MV. Potentiation effects of (&plusmn;)huprine X, a new acetylcholinesterase inhibitor, on nicotinic receptors in rat cortical synaptosomes. Neuropharmacology. 2004;46:95&ndash;102.","DOI":"10.1016\/j.neuropharm.2003.08.005"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Roman S, Badia A, Camps P, Mu&ntilde;oz-Torrero D, Clos MV. Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors. Brain Res. 2005;1061:73&ndash;79.","DOI":"10.1016\/j.brainres.2005.07.042"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2004.11.042"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.000299"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Wang D, Noda Y, Zhou Y, Nitta A, Furukawa H, Nabeshima T. Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model. Neuropharmacology. 2007;52:1179&ndash;1187.","DOI":"10.1016\/j.neuropharm.2006.12.007"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Wang D, Noda Y, Zhou Y, Nitta A, Furukawa H, Nabeshima T. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D<SUB>1<\/SUB> receptor-mediated neurotransmission. Neuropharmacology. 2007;53:379&ndash;389.","DOI":"10.1016\/j.neuropharm.2007.05.026"},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.07.032"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Dajas-Bailador FA, Heimala K, Wonnacott S. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca<SUP>2+<\/SUP> signals and neurotransmitter release. Mol Pharmacol. 2003;64:1217&ndash;1226.","DOI":"10.1124\/mol.64.5.1217"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Moriguchi S, Zhao X, Marszalec W, Yeh JZ, Fukunaga K, Narahashi T. Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Neuroscience. 2009;160:484&ndash;491.","DOI":"10.1016\/j.neuroscience.2009.02.055"},{"issue":"4","key":"55","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.neuroscience.2010.05.052","volume":"169","author":"KONRADSSON-GEUKEN A.","year":"2010","ISSN":"https:\/\/id.crossref.org\/issn\/0306-4522","issn-type":"print"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Wu HQ, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R. The astrocyte-derived <I>&alpha;<\/I>7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci. 2010;40:204&ndash;210.","DOI":"10.1007\/s12031-009-9235-2"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstr&ouml;m LH, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005;80:315&ndash;322.","DOI":"10.1016\/j.schres.2005.07.013"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001;50:521&ndash;530.","DOI":"10.1016\/S0006-3223(01)01078-2"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007;33:797&ndash;804.","DOI":"10.1093\/schbul\/sbl033"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004;56:255&ndash;260.","DOI":"10.1016\/j.biopsych.2004.06.006"},{"issue":"1","key":"61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pnpbp.2009.10.007","volume":"34","author":"PENNER J.","year":"2010","ISSN":"https:\/\/id.crossref.org\/issn\/0278-5846","issn-type":"print"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Castner SA, Goldman-Rakic PS, Williams GV. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl). 2004;174:111&ndash;125.","DOI":"10.1007\/s00213-003-1710-9"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol. 2005;5:101&ndash;106.","DOI":"10.1016\/j.coph.2004.08.008"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Wadenberg ML. Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des. 2010;16:358&ndash;370.","DOI":"10.2174\/138161210790170085"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Wiker C, Schilstr&ouml;m B, Sandb&auml;ck C, Wadenberg ML, Svensson TH. Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats. Int J Neuropsychopharmacol. 2008;11:845&ndash;850.","DOI":"10.1017\/S1461145708008730"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Wadenberg ML, Fj&auml;llstr&ouml;m AK, Federley M, Persson P, Stenqvist P. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor. Int J Neuropsychopharmacol. 2011;14:644&ndash;654.","DOI":"10.1017\/S1461145710000921"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Braff DL, Swerdlow NR, Geyer MA. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry. 1999;156:596&ndash;602.","DOI":"10.1176\/ajp.156.4.596"},{"key":"68","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.12.1325"},{"key":"69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropsychologia.2006.04.001"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Hohnadel E, Bouchard K, Terry AV Jr. Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology. 2007;52:542&ndash;551.","DOI":"10.1016\/j.neuropharm.2006.08.025"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Koda K, Ago Y, Kawasaki T, Hashimoto H, Baba A, Matsuda T. Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl). 2008;196:293&ndash;301.","DOI":"10.1007\/s00213-007-0962-1"},{"key":"72","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01342-7"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo\/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology. 2008;33:1217&ndash;1228.","DOI":"10.1038\/sj.npp.1301499"},{"key":"74","unstructured":"74 Tugal O, Yazici KM, Anil Yagcioglu AE, G&ouml;g&uuml;s A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol. 2004;7:117&ndash;123."},{"key":"75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.01080.x"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Gerlach J, Casey DE. Remoxipride, a new selective D<SUB>2<\/SUB> antagonist, and haloperidol in cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:103&ndash;112.","DOI":"10.1016\/0278-5846(90)90068-R"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Andersen MB, Werge T, Fink-Jensen A. The acetylcholinesterase inhibitor galantamine inhibits <I>d<\/I>-amphetamine-induced psychotic-like behavior in Cebus monkeys. J Pharmacol Exp Ther. 2007;321:1179&ndash;1182.","DOI":"10.1124\/jpet.107.119677"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003;6:347&ndash;352.","DOI":"10.1017\/S1461145703003675"},{"key":"79","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-25067"},{"key":"80","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.15.3.317"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Noda Y, Mouri A, Ando Y, Waki Y, Yamada SN, Yoshimi A, et al. Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1\/2 systems. Int J Neuropsychopharmacol. 2010;13:1343&ndash;1354.","DOI":"10.1017\/S1461145710000222"},{"key":"82","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00072-6"},{"key":"83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.231488998"},{"key":"84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0631749100"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Doetkotte R, Opitz K, Kiianmaa K, Winterhoff H. Reduction of voluntary ethanol consumption in alcohol-preferring Alko alcohol (AA) rats by desoxypeganine and galanthamine. Eur J Pharmacol. 2005;522:72&ndash;77.","DOI":"10.1016\/j.ejphar.2005.08.038"},{"key":"86","doi-asserted-by":"publisher","DOI":"10.1038\/332448a0"},{"key":"87","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(88)90193-1"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Cosgrove KP, Kloczynski T, Bois F, Pittman B, Tamagnan G, Seibyl JP, et al. Decreased Beta<SUB>2<\/SUB>*-nicotinic acetylcholine receptor availability after chronic ethanol exposure in nonhuman primates. Synapse. 2010;64:729&ndash;732.","DOI":"10.1002\/syn.20795"},{"key":"89","doi-asserted-by":"publisher","DOI":"10.1358\/mf.1999.21.4.538182"},{"key":"90","doi-asserted-by":"publisher","DOI":"10.1038\/4151030a"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Bruel-Jungerman E, Rampon C, Laroche S. Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses. Rev Neurosci. 2007;18:93&ndash;114.","DOI":"10.1515\/REVNEURO.2007.18.2.93"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Mora F, Segovia G, del Arco A. Aging, plasticity and environmental enrichment: structural changes and neurotransmitter dynamics in several areas of the brain. Brain Res Rev. 2007;55:78&ndash;88.","DOI":"10.1016\/j.brainresrev.2007.03.011"},{"key":"93","unstructured":"93 Malberg JE. Implications of adult hippocampal neurogenesis in antidepressant action. J Psychiatry Neurosci. 2004;29:196&ndash;205."},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 Perera TD, Park S, Nemirovskaya Y. Cognitive role of neurogenesis in depression and antidepressant treatment. Neuroscientist. 2008;14:326&ndash;338.","DOI":"10.1177\/1073858408317242"},{"key":"95","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2006.02.081"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007;18:391&ndash;418.","DOI":"10.1097\/FBP.0b013e3282ee2aa8"},{"key":"97","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2010.184"},{"key":"98","unstructured":"98 Gil-Bea FJ, Solas M, Mateos L, Winblad B, Ram&iacute;rez MJ, Cedazo-M&iacute;nguez A. Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation. Hippocampus. in press."},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML, et al. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J Pharmacol Exp Ther. 2006;316:679&ndash;694.","DOI":"10.1124\/jpet.105.093047"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Csernansky JG, Martin M, Shah R, Bertchume A, Colvin J, Dong H. Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology. 2005;30:2135&ndash;2143.","DOI":"10.1038\/sj.npp.1300761"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T10:31:37Z","timestamp":1686047497000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/116\/1\/116_11R01CR\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.11r01cr","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}